

Novocure Ltd
Form 3
January 06, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Longworth Todd Christopher		(Month/Day/Year)	Novocure Ltd [NVCR]	
(Last)	(First)	(Middle)	01/01/2017	
C/O NOVOCURE INC.,Â 20 VALLEY STREAM PKWY SUITE 300			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
MALVERN,Â PAÂ 19355			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (specify below)	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			General Counsel	<input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	2,022	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--------------------------------------------	----------------------------------------------------------	-----------------------------------------------------------------------------	-----------------------------------------------	-------------------------------------------	-------------------------------------------------------

Edgar Filing: Novocure Ltd - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Options to Buy Ordinary Shares	Â (1)	04/29/2022	Ordinary Shares	82,782	\$ 6.72	D	Â
Options to Buy Ordinary Shares	Â (2)	02/19/2023	Ordinary Shares	41,391	\$ 7.03	D	Â
Options to Buy Ordinary Shares	Â (3)	07/23/2023	Ordinary Shares	59,130	\$ 7.04	D	Â
Options to Buy Ordinary Shares	Â (4)	10/20/2024	Ordinary Shares	44,347	\$ 7.73	D	Â
Options to Buy Ordinary Shares	Â (5)	02/23/2025	Ordinary Shares	44,347	\$ 14.37	D	Â
Options to Buy Ordinary Shares	Â (6)	02/24/2026	Ordinary Shares	30,000	\$ 11.46	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Longsworth Todd Christopher C/O NOVOCURE INC. 20 VALLEY STREAM PKWY SUITE 300 MALVERN, PA 19355	Â	Â	Â General Counsel	Â

Signatures

/s/ Kimberly Burke, Attorney in fact for Todd Christopher Longsworth 01/06/2017

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Fully vested and currently exercisable as of the date hereof.
- (2) Options to buy 31,041 ordinary shares are vested and currently exercisable as of the date hereof. The remaining 10,350 ordinary shares will vest and become exercisable on February 20, 2017, subject to Mr. Longsworth's continued employment through such date.
- (3) Options to buy 44,346 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 14,784 ordinary shares will vest and become exercisable on July 24, 2017, subject to Mr. Longsworth's continued employment through such date.
Options to buy 22,172 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 22,175 ordinary shares will vest and become exercisable in equal installments on each of October 22, 2017 and 2018, subject to Mr. Longsworth's continued employment through such dates.
- (4) Options to buy 22,172 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 22,175 ordinary shares will vest and become exercisable in equal installments on each of October 22, 2017 and 2018, subject to Mr. Longsworth's continued employment through such dates.
- (5) Options to buy 11,086 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 33,261 ordinary shares will vest and become exercisable in equal installments on each of February 25, 2017, 2018 and 2019.
- (6) Options to buy 30,000 ordinary shares will vest and become exercisable in equal installments on each of February 24, 2017, 2018, 2019 and 2020, subject to Mr. Longsworth's continued employment through such dates.

Â

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.